| Title: |
First-in-man study of the PSMA Minibody IR800-IAB2M for molecularly targeted intraoperative fluorescence guidance during radical prostatectomy. |
| Authors: |
Hamdy, Freddie C.1,2 (AUTHOR) Freddie.Hamdy@nds.ox.ac.uk, Lamb, Alastair D.1,2 (AUTHOR), Tullis, Iain D. C.3 (AUTHOR), Verrill, Clare1,2 (AUTHOR), Rombach, Ines4,5 (AUTHOR), Rao, Srinivasa R.1 (AUTHOR), Colling, Richard1,2 (AUTHOR), Barber, Paul R.6 (AUTHOR), Volpi, Davide3 (AUTHOR), Barbera-Martin, Luis2 (AUTHOR), Lopez, J Francisco1,2 (AUTHOR), Omer, Altan2 (AUTHOR), Hewitt, Aimi1 (AUTHOR), Lovell, Shelagh1,2 (AUTHOR), Niederer, Jane1,2 (AUTHOR), Lambert, Adam1 (AUTHOR), Snoeck, Joke1 (AUTHOR), Thomson, Claire1 (AUTHOR), Leslie, Tom1,2 (AUTHOR), Bryant, Richard J.1,2 (AUTHOR) |
| Source: |
European Journal of Nuclear Medicine & Molecular Imaging. Aug2024, Vol. 51 Issue 10, p3009-3025. 17p. |
| Subject Terms: |
*PROSTATE-specific membrane antigen, *RADICAL prostatectomy, *SURGICAL excision, *PROSTATE cancer, *OPTICAL images |
| Abstract: |
Purpose: Prostate-specific membrane antigen (PSMA) is increasingly used to image prostate cancer in clinical practice. We sought to develop and test a humanised PSMA minibody IAB2M conjugated to the fluorophore IRDye 800CW-NHS ester in men undergoing robot-assisted laparoscopic radical prostatectomy (RARP) to image prostate cancer cells during surgery. Methods: The minibody was evaluated pre-clinically using PSMA positive/negative xenograft models, following which 23 men undergoing RARP between 2018 and 2020 received between 2.5 mg and 20 mg of IR800-IAB2M intravenously, at intervals between 24 h and 17 days prior to surgery. At every step of the procedure, the prostate, pelvic lymph node chains and extra-prostatic surrounding tissue were imaged with a dual Near-infrared (NIR) and white light optical platform for fluorescence in vivo and ex vivo. Histopathological evaluation of intraoperative and postoperative microscopic fluorescence imaging was undertaken for verification. Results: Twenty-three patients were evaluated to optimise both the dose of the reagent and the interval between injection and surgery and secure the best possible specificity of fluorescence images. Six cases are presented in detail as exemplars. Overall sensitivity and specificity in detecting non-lymph-node extra-prostatic cancer tissue were 100% and 65%, and 64% and 64% respectively for lymph node positivity. There were no side-effects associated with administration of the reagent. Conclusion: Intraoperative imaging of prostate cancer tissue is feasible and safe using IR800-IAB2M. Further evaluation is underway to assess the benefit of using the technique in improving completion of surgical excision during RARP. Registration: ISCRCTN10046036: https://www.isrctn.com/ISRCTN10046036. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Nuclear Medicine & Molecular Imaging is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
